Walter J. Lunsmann joined CellMosaic in 2016 with over 20 years of experience in drug delivery and development. In his role as the CEO of AqT™ Therapeutics, Walt is responsible for overall operaction and resources of  AqT™ Therapeutics, customer relationships, collaborations, and partnering activities. Walter has led product development teams through all phase of development, from discovery through ANDA and NDA filings. Prior to working at CellMosaic, Walter co-founded VivoPath, a discovery services provider which was acquired in 2014. At VivoPath, Walter led internal scientific and operational teams performing research and preclinical testing for clients. Before VivoPath, Walter led the Pharmaceutical Operations and Bioanalytical teams at Sirtris Pharmaceuticals, directing all GLP analytical and all GMP development and manufacturing activities to support clinical program requirements. Prior to Sirtris, Walter was Associate Director of Formulations for Synta Pharmaceuticals, responsible for Formulation and Manufacturing activities for Synta’s Discovery and Clinical programs in oncology and immunology. Walter previously was Study Director and Manager of Formulations for Cardinal Health at the Somerset, NJ Product Development Center. Walter received his M.S. in Chemical Engineering from MIT, his MBA from the Stern School of Business, and his B.S. in Chemical Engineering from Texas A&M University.

Yumei Huang is the founder of CellMosaic and inventor of AqT™ molecules. Dr. Huang has over 22 years of research experience in chemistry and biology with extensive knowledge of conjugation chemistry. In her role as the CSO of AqT™ Therapeutics, Dr. Huang is responsible for the company’s overall technological development. Dr. Huang started her career as a synthetic organic chemist in China and moved to the US in 1997 to pursue her PhD studies in bioorganic chemistry at CWRU. After graduation, Dr. Huang expanded her career into the biological field by joining the research group of Nobel Laureate H. Gobind Khorana at MIT. Previously, Dr. Huang worked at Ensemble, where she developed the core chemical technologies for biodetection and therapeutic programs. Prior to that, she worked at Johnson Matthey, developing the process for GMP production of APIs for various clients.